SENORES PHARMACEUTICALS LIMITED (NSE: SENORES) and Sun Pharma Advanced Research Company Limited (Sparc) (NSE: SPARC) are both listed in the Pharmaceuticals industry. SENORES PHARMACEUTICALS has a market capitalisation of ₹5,403 Cr and Sun Pharma Advanced Research Company ₹6,834 Cr, as of 16 Nov 2026. Their P/E ratios are 48.6 and 4.4 respectively. Return on equity is 13.68% for SENORES PHARMACEUTICALS and 2.77% for Sun Pharma Advanced Research Company. Over one year, SENORES PHARMACEUTICALS's share price is up 42.7% and Sun Pharma Advanced Research Company's is up 54.4%.
| Metric | SENORES PHARMACEUTICALS | Sun Pharma Advanced Research Company |
|---|---|---|
| NSE Symbol | SENORES | SPARC |
| BSE Code | 544319 | 532872 |
| Share Price | ₹1,171.10 | ₹206.50 |
| Market Cap | ₹5,403 Cr | ₹6,834 Cr |
| P/E Ratio | 48.6 | 4.4 |
| Return on Equity | 13.68% | 2.77% |
| Return on Assets | 6.05% | 79.74% |
| Beta (1Y) | 0.27 | 0.82 |
| 1-Year Price Change | +42.7% | +54.4% |
| 3-Month Price Change | -21.2% | +0.8% |
| 52-Week Range | ₹706.00 – ₹1,599.00 | ₹108.00 – ₹289.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹192 Cr | ₹30 Cr |
| Quarterly Net Profit | ₹37 Cr | ₹-24 Cr |
| Net Margin | 19.0% | -81.2% |
| EPS (Basic, Quarter) | ₹8.85 | ₹-0.75 |
| Results Basis | consolidated | consolidated |
| Headquarters | Ahmedabad, Gujarat | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as ma…
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clini…
Sun Pharma Advanced Research Company has a market capitalisation of ₹6,834 Cr, against ₹5,403 Cr for SENORES PHARMACEUTICALS as of 16 Nov 2026, about 1.3 times the size by market cap.
SENORES PHARMACEUTICALS has a P/E of 48.6 and Sun Pharma Advanced Research Company a P/E of 4.4 as of 16 Nov 2026.
SENORES PHARMACEUTICALS has a return on equity of 13.68% and Sun Pharma Advanced Research Company 2.77%.
SENORES PHARMACEUTICALS's share price is up 42.7% over one year and Sun Pharma Advanced Research Company's is up 54.4%.
SENORES PHARMACEUTICALS reported revenue of ₹192 Cr and net profit of ₹37 Cr for Q2 FY27. Sun Pharma Advanced Research Company reported revenue of ₹30 Cr and net profit of ₹-24 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.